Guggenheim analyst Yatin Suneja initiated Global Blood Therapeutics with a Buy rating and $75 price target, stating that he is optimistic about the approval of voxelotor under the FDA’s accelerated pathway. If approved, he thinks voxelotor could achieve about $1.45B in peak global sales, Suneja noted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.